By Michele Maatouk
Date: Friday 21 Aug 2026
(Sharecast News) - Pharmaceutlcal firms Moderna and MSD (Merck Sharp & Dohme (UK) Limited) said on on Wednesday that a personalised mRNA melanoma vaccine they are jointly developing had shown positive results in a first-ever late-stage trial.
No recent information was found.
| Currency | US Dollars |
| Share Price | $ 133.72 |
| Change Today | $ 0.91 |
| % Change | 0.69 % |
| 52 Week High | $156.45 |
| 52 Week Low | $94.97 |
| Volume | 15,611,990 |
| Shares Issued | 2,474.63m |
| Market Cap | $330,907m |
| RiskGrade | 92 |
| Strong Buy | 7 |
| Buy | 12 |
| Neutral | 8 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 27 |

| Time | Volume / Share Price |
| 16:02 | 2,639,807 @ $133.72 |
| 15:59 | 100 @ $133.82 |
| 15:59 | 100 @ $133.82 |
| 15:59 | 100 @ $133.82 |
| 15:59 | 125 @ $133.82 |
You are here: research